Role of HOXB7 in promoting gastric cancer progression and oxaliplatin (L-OHP) resistance.
Chemotherapy
HOXB7
L-OHP
drug resistance
gastric cancer
homeobox B7
oxaliplatin
Journal
International journal of clinical and experimental pathology
ISSN: 1936-2625
Titre abrégé: Int J Clin Exp Pathol
Pays: United States
ID NLM: 101480565
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
04
2020
accepted:
20
05
2020
entrez:
15
7
2020
pubmed:
15
7
2020
medline:
15
7
2020
Statut:
epublish
Résumé
Our study aimed to investigate the ways by which HOXB7 affects gastric cancer progression and oxaliplatin (L-OHP) resistance. First, the expression of HOXB7 in paired cancer and paracancerous tissues of L-OHP-sensitive and L-OHP-resistant gastric cancer patients was qualitatively and quantitatively analyzed by immunohistochemistry. Then, the expression of HOXB7 in these tissues was further quantitatively analyzed at protein and transcriptional levels. The expression of HOXB7 in the SGC-7901 L-OHP-resistant gastric cancer cell line was further verified by immunofluorescence, western blot, and RT-qPCR. In addition, by transfecting the SGC-7901 cell line, control (sh-con) and HOXB-7-silenced (sh-HOXB7) gastric cancer cell lines were created. Subsequently, the migratory and invasive abilities of these cells were determined by the transwell assay. The proliferation rate of both control and HOXB-7-silenced cells induced by varying concentrations of L-OHP was detected by the CCK-8 assay, while the degree of apoptosis in the same cells induced by 60 µM L-OHP was detected by flow cytometry. Results suggested that HOXB7 was overexpressed in both the tissues of L-OHP-resistant gastric cancer patients and the SGC-7901 gastric cancer cell line. Moreover, HOXB7 promoted the migratory and invasive abilities of gastric cancer cells. By silencing HOXB7 protein expression, the proliferation rate of L-OHP-resistant gastric cancer cells decreased considerably, while their degree of apoptosis increased significantly. These results showed that HOXB7 promoted gastric cancer progression and L-OHP resistance.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Our study aimed to investigate the ways by which HOXB7 affects gastric cancer progression and oxaliplatin (L-OHP) resistance.
METHODS
METHODS
First, the expression of HOXB7 in paired cancer and paracancerous tissues of L-OHP-sensitive and L-OHP-resistant gastric cancer patients was qualitatively and quantitatively analyzed by immunohistochemistry. Then, the expression of HOXB7 in these tissues was further quantitatively analyzed at protein and transcriptional levels. The expression of HOXB7 in the SGC-7901 L-OHP-resistant gastric cancer cell line was further verified by immunofluorescence, western blot, and RT-qPCR. In addition, by transfecting the SGC-7901 cell line, control (sh-con) and HOXB-7-silenced (sh-HOXB7) gastric cancer cell lines were created. Subsequently, the migratory and invasive abilities of these cells were determined by the transwell assay. The proliferation rate of both control and HOXB-7-silenced cells induced by varying concentrations of L-OHP was detected by the CCK-8 assay, while the degree of apoptosis in the same cells induced by 60 µM L-OHP was detected by flow cytometry.
RESULTS AND CONCLUSION
CONCLUSIONS
Results suggested that HOXB7 was overexpressed in both the tissues of L-OHP-resistant gastric cancer patients and the SGC-7901 gastric cancer cell line. Moreover, HOXB7 promoted the migratory and invasive abilities of gastric cancer cells. By silencing HOXB7 protein expression, the proliferation rate of L-OHP-resistant gastric cancer cells decreased considerably, while their degree of apoptosis increased significantly. These results showed that HOXB7 promoted gastric cancer progression and L-OHP resistance.
Types de publication
Journal Article
Langues
eng
Pagination
1381-1389Informations de copyright
IJCEP Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Handb Exp Pharmacol. 2018;248:623-624
pubmed: 30810864
Gastric Cancer. 2017 Jan;20(1):104-115
pubmed: 26759228
DNA Cell Biol. 2018 Nov;37(11):917-924
pubmed: 30388035
Life Sci. 2019 Feb 1;218:1-7
pubmed: 30537478
Crit Rev Oncol Hematol. 2019 Jul;139:1-6
pubmed: 31112877
J Gastroenterol Hepatol. 2016 Oct;31(10):1717-1726
pubmed: 26968988
Am J Physiol Cell Physiol. 2018 Nov 1;315(5):C675-C686
pubmed: 30067384
Medicine (Baltimore). 2019 May;98(20):e15696
pubmed: 31096513
FASEB J. 2019 Jun;33(6):7143-7154
pubmed: 30844312
Eur J Cancer. 2019 Sep;118:190
pubmed: 31331779
Oncotarget. 2017 Jul 18;8(29):47121-47135
pubmed: 28454092
Pharmaceuticals (Basel). 2019 Feb 20;12(1):
pubmed: 30791601
Blood Adv. 2017 May 04;1(12):733-747
pubmed: 29296717
Eur J Cancer Care (Engl). 2019 May;28(3):e13012
pubmed: 30748055
BMJ Open. 2019 Jul 23;9(7):e029638
pubmed: 31340970
Lab Invest. 2019 Jun;99(6):736-748
pubmed: 30664713
J Cell Biochem. 2018 Nov 28;:
pubmed: 30484890
J Gastric Cancer. 2018 Sep;18(3):242-252
pubmed: 30276001
Oncotarget. 2017 Jan 3;8(1):1247-1261
pubmed: 27901487
J Cancer. 2019 Apr 25;10(8):1923-1929
pubmed: 31205551